EU/3/14/1418

About

On 15 January 2015, orphan designation (EU/3/14/1418) was granted by the European Commission to Theravectys, France, for a lentiviral vector pseudotyped by the New-Jersey serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I and p30II HTLV-1 proteins for the treatment of adult T-cell leukaemia/lymphoma.

Key facts

Active substance
A lentiviral vector pseudotyped by the New-Jersey serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I and p30II HTLV-1 proteins
Disease / condition
Treatment of adult T-cell leukaemia/lymphoma
Date of decision
15/01/2015
Outcome
Positive
Orphan decision number
EU/3/14/1418

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

THERAVECTYS
1 mail du Pr Georges Mathe
94800 Villejuif
France
Tel. +33 1 43 90 19 20
Fax +33 1 84 16 30 31
E-mail: regulatory@theravectys.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating